Puma Biotechnology (NASDAQ:PBYI - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Thursday.
Separately, HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.
Check Out Our Latest Research Report on PBYI
Puma Biotechnology Stock Performance
Shares of PBYI stock traded up $0.12 during mid-day trading on Thursday, reaching $3.36. The stock had a trading volume of 89,747 shares, compared to its average volume of 435,620. The firm's 50 day simple moving average is $3.07 and its 200 day simple moving average is $3.07. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a one year low of $2.23 and a one year high of $4.13. The firm has a market cap of $166.51 million, a PE ratio of 6.95 and a beta of 1.29.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. On average, analysts forecast that Puma Biotechnology will post 0.31 EPS for the current year.
Hedge Funds Weigh In On Puma Biotechnology
Several hedge funds and other institutional investors have recently modified their holdings of PBYI. Gateway Wealth Partners LLC bought a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $31,000. Tower Research Capital LLC TRC lifted its position in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 6,351 shares during the period. Graham Capital Management L.P. bought a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $33,000. ProShare Advisors LLC bought a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $36,000. Finally, C2C Wealth Management LLC bought a new position in shares of Puma Biotechnology during the 4th quarter worth approximately $37,000. Institutional investors own 61.29% of the company's stock.
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
See Also
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
